{
  "docId": "019de076-0bfb-77a4-9766-824e83d61c36",
  "docSlug": "78f42e9d8d70fea2dc2370a17955f7e7",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 52 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 44,
  "pageCount": 52,
  "prevPage": 43,
  "nextPage": 45,
  "slideType": "other",
  "function": "illustrate_case",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "Includes clinical data points for EML4-ALK v3, G1202R, G1269A, and I1322M.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/44",
  "deckHref": "/decks/019de076-0bfb-77a4-9766-824e83d61c36",
  "deckJsonHref": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json",
  "deckAnchorHref": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-44",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.48,
        "x": 0.46,
        "y": 0.65
      },
      "kind": "chart",
      "text": "ALK Allele Fraction Best % Change from Baseline",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9be4293c-fd9c-490d-bfb6-ad525b6d1e9d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.48,
        "x": 0.46,
        "y": 0.275
      },
      "kind": "image",
      "text": "Baseline and 20 weeks CT scans",
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9d3624e2-ea06-4f78-81da-3a77dd1a444d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.38,
        "x": 0.08,
        "y": 0.52
      },
      "kind": "list",
      "text": "Complete clearance of ALK mutant alleles in ctDNA by 6 weeks; Partial Response by RECIST 1.1 (-36%) at 6 weeks, confirmed and persisting (-62%) at 20 weeks; Treatment well tolerated; Continues to receive NVL-655 for ~5 months with an ongoing PR",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "83443f6a-2d48-42c5-ac71-6fa0d3159ac4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.38,
        "x": 0.08,
        "y": 0.22
      },
      "kind": "paragraph",
      "text": "Diagnosis: EML4-ALK v3/b NSCLC with ALK mutations G1202R, G1269A, and I1322M. Prior treatments: 8 prior lines of therapy, including crizotinib, ceritinib, alectinib, brigatinib, lorlatinib, and platinum-based chemo. Sites of disease: Including lung, liver, and CNS.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "31be3ea5-c518-4878-8b31-a38ad7812e48",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.65,
        "x": 0.07,
        "y": 0.89
      },
      "kind": "source-note",
      "text": "Data as of 8 August 2023. CNS, central nervous system; NSCLC, Non-small cell lung cancer; PR, partial response; QD, once daily; TKI, tyrosine kinase inhibitor. Source: Lin J.J. et al., AACR-NCI-EORTC 2023.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d2470ff4-24f4-4d21-bbbe-4245d93f9a3e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "Case Study | NVL-655 Induced Response in a TKI-Refractory Patient with ALK G1202R/G1269A Resistance Mutations",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9ae006bd-518c-4df9-8315-c1c877706c23",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Before-After-Bridge",
      "slug": "before-after-bridge",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "a4a8fdb0-6970-4bde-98c7-146078e5ab61",
      "evidence": "Baseline and 20 weeks CT scans",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 45,
      "from": 13,
      "beatId": "11ad9310-8f34-4e49-9752-09ee2f990465",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "Slides 13-45: Various traction slides, including preclinical and clinical trial results",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}